Skip to main content
Caplight Logo









AptamiR Therapeutics

AptamiR Therapeutics

Private
Naples, FloridaHealthcare & Life Scienceshttps://www.aptamir.com/

Last Round

Seed

Sep 21, 2015

Total Funding Raised

$3M

Company Overview

AptamiR Therapeutics is a biotechnology company that develops microRNA-based oligonucleotide therapeutics to treat cardiometabolic disorders and ovarian cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

oligonucleotide therapeuticsmicroRNA therapeuticsantagomirRNA therapeuticscardiometabolic diseaseMASH treatmentobesity treatmentmetabolic dysfunction-associated steatohepatitisovarian cancerPeptide Nucleic AcidPNAgene network modulationpreclinical developmentmulti-target therapeuticsweight loss drugdrug discoveryNASH treatmentpharmaceutical licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AptamiR Therapeutics Comparables

Compare AptamiR Therapeutics with similar companies based on industry and business-model similarity.

AptamiR Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Resalis Therapeutics
86%
Novo Nordisk
73%
miRecule, Inc.
71%

AptamiR Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 21, 2015

AptamiR Therapeutics Investors

Notable investors and investment history

AptamiR Therapeutics investors
InvestorRounds
Austin Technology IncubatorSeed, Accelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 21, 2015

    $3M raised with Austin Technology Incubator participating.

AptamiR Therapeutics Filings

Explore SEC and related filing metadata, where available.

AptamiR Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AptamiR Therapeutics's valuation, stock price, and market status.

Is AptamiR Therapeutics a public or private company?

AptamiR Therapeutics is a private company.

What is the current stock price of AptamiR Therapeutics?

AptamiR Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is AptamiR Therapeutics worth (valuation)?

Valuation information for AptamiR Therapeutics is not publicly available.

Can I buy AptamiR Therapeutics stock?

AptamiR Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AptamiR Therapeutics's last funding round?

Funding round information for AptamiR Therapeutics is not publicly available.

Who are the main investors in AptamiR Therapeutics?

Investor information for AptamiR Therapeutics is not publicly disclosed.

Will AptamiR Therapeutics IPO soon?

No public IPO plans have been announced for AptamiR Therapeutics.

How can I track AptamiR Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AptamiR Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNaples, Florida
Employee Range1
Year Founded2012
Last FundingSep 21, 2015

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?